Biktarvy has now been in clinical use since 2018 and has accumulated more than five years of long-term follow-up data from its phase 3 trials and real-world cohorts. For most patients it remains well-tolerated over the long term — the discontinuation rate due to side effects in controlled studies was under 2%. But several organ systems warrant ongoing monitoring, and a subset of patients experience clinically meaningful effects over years of use. This page reviews every documented long-term concern, what the 5-year data actually shows, and what monitoring is appropriate.
Overview: Long-Term Safety Profile of Biktarvy
Biktarvy’s long-term safety data comes primarily from two pivotal phase 3 trials — GS-US-380-1489 and GS-US-380-1490 — which have published results out to 144 weeks, supplemented by real-world registry data and observational cohort studies extending to five years. The overall picture is reassuring: Biktarvy maintained viral suppression in the vast majority of patients who stayed on it, with very low rates of treatment discontinuation due to adverse effects.
The long-term concerns that have emerged are not acute toxicities but slow, cumulative effects on specific organ systems — primarily metabolic (weight, lipids, glucose), renal (kidney function markers), and bone density. None of these require routine changes in most patients, but all require systematic monitoring.
Key distinction: Most side effects that cause people to stop Biktarvy happen in the first 8–12 weeks. Long-term effects are characterised by gradual changes in biomarkers — kidney function, bone density, lipids — that rarely cause symptoms but can compound over years if not monitored. Routine annual labs catch the vast majority of clinically meaningful changes before they require intervention.
Kidney Effects Over Time
Renal monitoring is a standard component of HIV care for everyone on antiretroviral therapy, but Biktarvy’s kidney profile is meaningfully better than the older tenofovir formulation it replaced.
TAF vs TDF: Why Biktarvy Is Safer for Kidneys
Biktarvy contains tenofovir alafenamide (TAF), a prodrug that delivers tenofovir directly into cells at much lower plasma concentrations than tenofovir disoproxil fumarate (TDF). Lower plasma tenofovir means substantially less exposure in the kidney tubules — the site where TDF-related nephrotoxicity occurred. Long-term data consistently show that patients on TAF-based regimens have lower rates of proteinuria, tubular dysfunction markers (such as beta-2-microglobulin and RBP), and eGFR decline compared to historical TDF cohorts.
In patients who switched from TDF-containing regimens to Biktarvy, kidney function markers typically improve after the switch — often within the first 24–48 weeks. This improvement persists at five years in published follow-up data.
What Kidney Monitoring Is Still Needed
- Serum creatinine and calculated eGFR — at baseline and every 6–12 months
- Urine protein:creatinine ratio (UPCR) or dipstick proteinuria — annually or if eGFR declines
- Phosphate — at baseline and annually, particularly in patients with bone or tubular disease history
- If eGFR falls below 30 mL/min/1.73m², Biktarvy use requires specialist review
For most patients with normal kidney function at baseline: Biktarvy’s long-term kidney profile is excellent. The five-year data shows no meaningful progressive renal decline in patients who started with normal eGFR.
Bone Density Effects Over Time
Bone density loss is one of the better-documented long-term effects of antiretroviral therapy in general, and Biktarvy compares favourably to TDF-based regimens. In the Biktarvy phase 3 trials, patients showed significantly smaller BMD declines at the hip and spine compared to patients on Atripla (efavirenz/TDF/FTC). In patients who switched from TDF-based regimens to Biktarvy, BMD improved at both the spine and hip, with gains maintained at the 96-week and 144-week follow-up points.
Bone Monitoring Recommendations
- Baseline DEXA scan is recommended for postmenopausal women, men over 50, and patients with additional fracture risk factors
- Routine DEXA is not recommended for all patients on Biktarvy — the risk-benefit ratio does not support universal screening in younger, otherwise healthy adults
- Calcium and vitamin D supplementation is appropriate for patients at risk; note the 2-hour timing rule — calcium supplements must be separated from Biktarvy by at least 2 hours
- Weight-bearing exercise mitigates ART-associated bone loss and is recommended for all patients
Metabolic Effects: Weight, Lipids, and Glucose
Metabolic changes are the most clinically significant long-term concern for most patients on Biktarvy. These effects compound over years and contribute to cardiovascular risk — already elevated in people living with HIV due to chronic inflammation and immune activation.
Weight Gain
Mean weight gain of approximately 2 kg at 48 weeks and 4 kg at 96 weeks has been reported across Biktarvy phase 3 trials. For a full breakdown of mechanisms, risk factors, and management, see the Biktarvy weight gain page.
Lipid Changes
Patients on Biktarvy typically show modest increases in total cholesterol, LDL cholesterol, and triglycerides compared to TDF-based regimens. In clinical trial data, mean increases in LDL cholesterol of 8–12 mg/dL and total cholesterol of 15–20 mg/dL have been reported over 96 weeks.
Glucose and Insulin Resistance
Some observational studies have reported modest increases in fasting glucose and insulin resistance in patients on long-term INSTI-based regimens. People living with HIV already have approximately 1.5× the background rate of type 2 diabetes compared to the general population; monitoring on Biktarvy is therefore clinically appropriate.
Cardiovascular risk context: The combination of modest weight gain, lipid increases, and potential insulin resistance over years creates a cumulative cardiovascular risk profile that warrants active management. Annual fasting lipids, glucose, and HbA1c alongside blood pressure measurement are standard of care.
Liver Effects Over Time
Biktarvy does not cause direct hepatotoxicity at therapeutic doses. Grade 3 or 4 liver enzyme elevations were rare in phase 3 trials and were primarily seen in patients with underlying hepatitis B or C co-infection.
Hepatitis B co-infected patients must never stop Biktarvy abruptly. Emtricitabine and tenofovir alafenamide in Biktarvy also suppress hepatitis B. Stopping without a replacement HBV-active regimen can trigger severe hepatitis B reactivation, including acute liver failure. Any regimen change in HBV co-infected patients must be managed by a specialist with liver function monitored for at least 12 weeks after any change.
Neurological and Psychiatric Effects Over Time
Neurological side effects are much less common with Biktarvy than with efavirenz-based regimens. Long-term follow-up data do not suggest progressive neurological toxicity from Biktarvy in otherwise neurologically healthy patients.
- Insomnia and sleep disturbance were reported in approximately 3–5% of patients; for most this resolved within the first 12 weeks.
- Depression and mood changes were reported at rates comparable to background rates in the HIV-positive population.
- Cognitive effects — Biktarvy does not carry the neuropsychiatric warning that efavirenz does, and there is no evidence of Biktarvy-specific long-term cognitive effects.
Recommended Monitoring Schedule on Long-Term Biktarvy
Long-Term Side Effects by Organ System — Summary Table
| System | Effect | Severity | Evidence at 5 Years | Action |
|---|---|---|---|---|
| Metabolic | Weight gain (~4 kg average) | Moderate | Confirmed; slows after yr 1 | Annual weight, BMI, waist |
| Metabolic | LDL + total cholesterol rise | Moderate | Confirmed; modest (~10–15 mg/dL) | Annual fasting lipids; statin if indicated |
| Metabolic | Fasting glucose / insulin resistance | Low–Moderate | Signal in cohorts; modest effect | Annual HbA1c + fasting glucose |
| Renal | eGFR decline | Low (TAF) | Better than TDF; stable at 5 yrs | Annual eGFR + urinalysis |
| Renal | Tubular proteinuria | Low (TAF) | Significantly less than TDF | Annual UPCR if renal risk |
| Bone | BMD decline | Low (TAF) | Modest early decline; stabilises; better than TDF | DEXA at baseline if risk factors |
| Liver | HBV flare on discontinuation | High risk (HBV+) | Well established | Never stop without HBV-active replacement |
| Liver | ALT/AST elevation | Low | Rare in non-HBV/HCV patients | Annual LFTs |
| CNS | Insomnia / sleep disturbance | Low | 3–5% at initiation; most resolve by wk 12 | Monitor at follow-up |
| CNS | Depression / mood change | Uncertain | Reported; confounded by HIV-related depression | Mental health screen at each visit |
How Long Can You Stay on Biktarvy?
There is no defined maximum duration for Biktarvy use. For patients who are virologically suppressed, tolerating the drug well, and have no emerging metabolic complications, there is no evidence-based reason to switch. Reasons that may prompt a considered switch include persistent clinically significant weight gain causing metabolic complications, significant renal deterioration (rare on TAF), a planned switch to long-acting injectable therapy, or changes in health status that make co-medication management complex. Any switch decision should be made jointly with your HIV specialist.
Frequently Asked Questions
Yes — Biktarvy has one of the best long-term tolerability profiles of any antiretroviral regimen currently available. In five-year follow-up data, fewer than 2% of patients discontinued due to side effects, and viral suppression was maintained in 98.6% of those who stayed on the drug. The organ systems that require monitoring — kidneys, bones, metabolic — show manageable changes that are substantially better than the TDF-based regimens Biktarvy replaced in most patients.
Not in patients with normal kidney function at baseline, based on current 5-year data. Biktarvy uses tenofovir alafenamide (TAF), which delivers active drug into cells at much lower plasma concentrations than the older TDF formulation — substantially reducing kidney tubule exposure. Long-term studies show stable eGFR and lower rates of proteinuria on TAF compared to TDF. Patients with pre-existing CKD or renal risk factors require closer monitoring.
There is a modest early decline in bone mineral density in the first 24–48 weeks of Biktarvy therapy, followed by stabilisation. This is substantially less than was observed with TDF-based regimens. In patients who switched from TDF to Biktarvy, bone density actually improved, with gains maintained at the 144-week follow-up point.
Biktarvy does not cause direct hepatotoxicity in patients without underlying liver disease. The main liver-related risk is in hepatitis B co-infected patients: stopping Biktarvy without replacing its FTC and TAF components can trigger a severe hepatitis B reactivation flare. Any regimen change in an HBV co-infected patient must be managed by a specialist.
There is no defined upper limit. For patients who are virologically suppressed, tolerating the drug well, and have no emerging metabolic or organ complications, there is no evidence-based reason to switch. The 5-year data show continued efficacy and no progressive safety signal that would prompt a routine switch in stable patients.
Biktarvy itself has not been shown to increase cardiovascular events in clinical trials. However, the combination of modest long-term effects — weight gain, modest LDL increase, potential insulin resistance — creates a cumulative metabolic picture that contributes to cardiovascular risk in susceptible patients. Active management of cardiovascular risk factors is standard of care for all people living with HIV, regardless of regimen.
This article was reviewed by Dr. Jürgen Epple and written by Richard Boehme in accordance with SunnyPharma’s Editorial Policy. Content is reviewed for clinical accuracy, updated when guidelines change, and written to inform — not replace — the advice of a qualified healthcare provider.
References
- Gallant J, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine (GS-US-380-1489). Lancet. 2017;390(10107):2063–2072.
- Sax PE, et al. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1. Lancet HIV. 2017;4(4):e154–e160.
- Orkin C, et al. Long-term efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide at 144 weeks. HIV Clin Trials. 2021;22(3):108–116.
- Gilead Sciences. Biktarvy US Prescribing Information. January 2024.
- DHHS Panel on Antiretroviral Guidelines. Updated January 2025. clinicalinfo.hiv.gov
- Sax PE, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020;71(6):1379–1389.
- Mills A, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed adults: renal and bone outcomes at 96 weeks. Clin Infect Dis. 2019;68(12):2062–2072.